Gastric and duodenal ulcers, chronic gastritis associated with H. pylori.
Hypersensitivity to lansoprazole, clarithromycin or to other macrolide antibiotics, tinidazole or to other 5-nitroimidazole derivatives. Concomitant use with the following agents: atazanavir, astemizole, cisapride, pimozide, terfenadine (as this may lead to prolongation of the QT interval and the development of cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation and pirouette ventricular tachycardia); ergot alkaloids, such as ergotamine, dihydroergotamine (as this may lead to ergotoxicity), HMG-CoA reductase inhibitors (statins), which are extensively metabolized by CYP3A4, such as lovastatin or simvastatin (due to an increased risk of myopathy). Pathological changes in the blood.
Organic lesions of the nervous system. Concomitant use of the drug (and other potent CYP3A4 inhibitors) with colchicine. Concomitant use of clarithromycin with ticagrelor or ranolazine. Concomitant use of the drug and oral midazolam. QT prolongation or a history of ventricular arrhythmias, including pirouette ventricular tachycardia (torsades de pointes). Severe hepatic failure and concomitant renal failure. Hypokalemia.
Dosage & Administration
The decision on the treatment regimen, doses and timing of treatment should be made by a physician. Recommended regimen and dosage: 1 strip or blister containing 2 capsules of lansoprazole, 2 tablets of clarithromycin and 2 tablets of tinidazole, designed for 1 day of treatment. In the morning take 1 capsule of lansoprazole and 1 tablet of clarithromycin and tinidazole, repeat the drug in the evening.
In addition to taking the combined daily kit, it is necessary to take 250 mg of clarithromycin 2 times a day, together with the proposed scheme.
A 14-day therapy that meets modern standards is recommended.